Skip to main content
Matthew Galsky, MD, Oncology, New York, NY, The Mount Sinai Hospital

MatthewDGalskyMD

Oncology • New York, NY

Genitourinary Oncology, Hematologic Oncology

Professor Director, Genitourinary Medical Oncology Director, Novel Therapeutics Program Mount Sinai School of Medicine

Request Appointment

Overview of Dr. Galsky

Dr. Matthew Galsky is an oncologist in New York, NY and is affiliated with The Mount Sinai Hospital. He received his medical degree from Tufts University School of Medicine and has been in practice 19 years. Dr. Galsky accepts several types of health insurance, listed below. He is one of 191 doctors at The Mount Sinai Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1998 - 2001
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1998

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2001 - 2025
  • NV State Medical License
    NV State Medical License 2006 - 2011
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Identification of microR-106b as a Prognostic Biomarker of p53-like Bladder Cancers by ActMiR  
    Matthew D Galsky, William K Oh, Nature

Lectures

  • A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in ... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (m... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Is there a difference in PD-1 / PD-L1 inhibitors for urothelial cancer? Continuous Evolution of a Phase I Trial Into An FDA Package 
    2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

  • Immunotherapy After Surgery Is Beneficial for High-Risk Bladder Cancer Patients
    Immunotherapy After Surgery Is Beneficial for High-Risk Bladder Cancer PatientsApril 3rd, 2023
  • CheckMate 274 Follow up Data Boost Nivolumab Potential for High-Risk Bladder Cancer
    CheckMate 274 Follow up Data Boost Nivolumab Potential for High-Risk Bladder CancerMarch 8th, 2023
  • CheckMate 274: Continued Disease-Free Survival Benefits with Adjuvant Nivolumab in High-Risk Urothelial Carcinoma
    CheckMate 274: Continued Disease-Free Survival Benefits with Adjuvant Nivolumab in High-Risk Urothelial CarcinomaMarch 8th, 2023
  • Join now to see all

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    First Health PPO
    GHI PPO
    Great West PPO
    HIP of New York - Select PPO
    Humana ChoiceCare Network PPO
    MagnaCare PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Matthew Galsky, Dr. Matthew Galsky, MD, Dr. M Galsky, Dr. Matthew D Galsky